CUSIP 359616109 · who reports it, how much, and how much it matters to them
24 of the 720 hedge fund managers we track reported shares of Fulcrum Therapeutics, Inc. (Nasdaq: FULC) on Form 13F for 30 June 2026. Between them they reported USD 95m. The largest position belongs to ECOR1 Capital, at USD 24m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | ECOR1 Capital3 funds on PPLI.com | USD 24m | 1.2% |
| 2 | Suvretta Capital Management4 funds on PPLI.com | USD 13m | 0.2% |
| 3 | D. E. Shaw & Co.15 funds on PPLI.com | USD 11m | 0.0% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 9.9m | 0.0% |
| 5 | Adage Capital Management1 fund on PPLI.com | USD 7.3m | 0.0% |
| 6 | Renaissance Technologies13 funds on PPLI.com | USD 6m | 0.0% |
| 7 | Millennium Management6 funds on PPLI.com | USD 5.4m | 0.0% |
| 8 | Marshall Wace LLP84 funds on PPLI.com | USD 5m | 0.0% |
| 9 | Two Sigma Investments35 funds on PPLI.com | USD 3m | 0.0% |
| 10 | Balyasny Asset Management25 funds on PPLI.com | USD 2.5m | 0.0% |
| 11 | POINT72 Asset Management17 funds on PPLI.com | USD 2.4m | 0.0% |
| 12 | Boothbay Fund Management2 funds on PPLI.com | USD 1.1m | 0.0% |
| 13 | Engineers Gate Manager1 fund on PPLI.com | USD 886,000 | 0.0% |
| 14 | Entrypoint Capital1 fund on PPLI.com | USD 795,000 | 0.2% |
| 15 | Squarepoint Ops7 funds on PPLI.com | USD 463,000 | 0.0% |
| 16 | Verdad Advisers6 funds on PPLI.com | USD 458,000 | 0.4% |
| 17 | Rangeley Capital6 funds on PPLI.com | USD 420,000 | 0.4% |
| 18 | Prelude Capital Management9 funds on PPLI.com | USD 248,000 | 0.0% |
| 19 | LMR Partners2 funds on PPLI.com | USD 110,000 | 0.0% |
| 20 | Scientech Research2 funds on PPLI.com | USD 105,000 | 0.1% |
| 21 | Graham Capital Management18 funds on PPLI.com | USD 91,745 | 0.0% |
| 22 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 58,844 | 0.0% |
| 23 | Jain Global1 fund on PPLI.com | USD 55,852 | 0.0% |
| 24 | Brevan Howard Capital Management39 funds on PPLI.com | USD 47,939 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | ECOR1 Capital | USD 24m | 1.2% |
| 2 | Verdad Advisers | USD 458,000 | 0.4% |
| 3 | Rangeley Capital | USD 420,000 | 0.4% |
| 4 | Suvretta Capital Management | USD 13m | 0.2% |
| 5 | Entrypoint Capital | USD 795,000 | 0.2% |
| 6 | Scientech Research | USD 105,000 | 0.1% |
| 7 | Prelude Capital Management | USD 248,000 | 0.0% |
| 8 | Boothbay Fund Management | USD 1.1m | 0.0% |
| 9 | Engineers Gate Manager | USD 886,000 | 0.0% |
| 10 | Adage Capital Management | USD 7.3m | 0.0% |
Fulcrum Therapeutics, Inc. trades under the symbol FULC on the Nasdaq. Its CUSIP, the code used on Form 13F, is 359616109.
24 of the 720 hedge fund managers PPLI.com tracks reported Fulcrum Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by ECOR1 Capital (USD 24m), Suvretta Capital Management (USD 13m), D. E. Shaw & Co. (USD 11m), Citadel Advisors (USD 9.9m) and Adage Capital Management (USD 7.3m).
24 managers in our coverage reported it, and between them they run 359 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
ECOR1 Capital, where the position was 1.2% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Fulcrum Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.